Key result
Aromatase inhibitor use had a similar risk of cardiac ischemia (HR 0.97; 95% CI 0.78-1.22) and stroke compared with tamoxifen use, but an increased risk of other CVD events.
Why the study?
Does aromatase inhibitor use increase the risk of cardiovascular disease compared to tamoxifen in postmenopausal breast cancer survivors?
Cohort (n=13,273)
Yes
Does aromatase inhibitor use increase the risk of cardiovascular disease compared to tamoxifen in postmenopausal breast cancer survivors?
Hazard Ratio: 0.97 (95% CI 0.78–1.22)
Aromatase inhibitor use in postmenopausal breast cancer survivors is not associated with an increased risk of cardiac ischemia or stroke compared to tamoxifen, but may increase the risk of other cardiovascular events such as dysrhythmia and valvular dysfunction.
No takes yet. Share an insight, caveat, or question.
May support closer CVD monitoring in AI-treated survivors; leaves open causal risks versus tamoxifen after adjustment.
Haque et al. (2016) conducted a cohort in Hormone receptor-positive breast cancer (n=13,273). Aromatase inhibitor (AI) use vs. Tamoxifen use was evaluated on Cardiac ischemia (myocardial infarction and angina) (HR 0.97, 95% CI 0.78-1.22). Aromatase inhibitor use had a similar risk of cardiac ischemia (HR 0.97; 95% CI 0.78-1.22) and stroke compared with tamoxifen use, but an increased risk of other CVD events.